First quarter shows Mylan still struggling in USA and Europe

7 May 2019
mylan_big

A miss in first quarter revenue estimates, coupled with manufacturing troubles at one of its US facilities, conspired to send Mylan (Nasdaq: MYL) shares plummeting nearly 20% on Tuesday morning in New York.

The firm reported total revenues of $2.5 billion, down 7% compared to the prior year period, and adjusted diluted earnings per share (EPS) of $0.82, down 15% over the prior year period.

The decrease in net sales, which included a 14% decline in Europe and 6% in North America, was partially offset by a 3% increase in the Rest of World segment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics